Aspen Labs Mexico – Carlos Abelleyra Cordero, CEO Spanish LATAM
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Ranked as the ninth largest generic company in the world, South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. The Group currently has 50 business units , 26 manufacturing facilities at 18 sites on 6 continents and approximately 8200 employees. In Latin America Aspen supplies a range of quality affordable products through its affiliate companies in Mexico, Argentina, Brazil and Venezuela as well as across the rest of Latin America in countries such as Chile, Colombia, Ecuador and the Carricam territories. Aspen sees Latin America as one of its key strategic regions with significant growth potential within the Group, and continues to seek opportunities to establish a greater presence in other Latin American countries.
Contact Details
Aspen Labs, S.A. De C.V.
Av. Insurgentes Sur 1685
Col. Guadalupe Inn, Del. Alvaro Obregón
C.P. 01020 México D.F.
Tel: +52 (55) 9126 0860
Website: aspenlabs.com.mx
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas of focus. As Chairman of the Board of Menarini Mexico,…
Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the…
The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in…
Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
For Cristóbal Thompson, Executive Director of AMIIF, health is a formidable measure of productivity and competitiveness that Mexico can no longer overlook if it is to sustain robust economic growth. He…
Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of…
Senator Salvador Brito, President of the Health Commission at the Mexican Senate, talks about increasing access to quality healthcare services among the most vulnerable groups in Mexican society, improving and…
Servier GM Florent Darchez, reveals how he turned around a Mexico affiliate that was losing market share to achieve and impressive sales growth of 30 percent a year. Darchez also…
In part two of a two-part interview (read part one here), Mikel Arriola of the IMSS discusses the strategic roadmap IMSS will follow under his tenure with regards to innovation…
In part one of a two-part interview (read part two here), Mikel Arriola, the recently appointed general director of IMSS (Mexican Social Security Institute), which provides health-related services to more…
Rafael Suarez, general manager of Ferring in Mexico, explains how the Swiss biopharmaceutical company is adapting to the recent dynamics affecting both the Mexican public and private sectors. He outlines…
See our Cookie Privacy Policy Here